REGENXBIO FY2025 EPS Forecast Reduced by Leerink Partnrs

Key Points

• Leerink Partners has revised its FY2025 earnings per share estimate for REGENXBIO to a loss of ($2.32), significantly lower than the previous estimate of ($1.64).
• The consensus estimate for REGENXBIO's full-year earnings currently stands at a loss of ($4.84) per share, reflecting broader challenges within the company.
• Multiple analysts have provided mixed ratings on REGENXBIO, with a "buy" rating from Chardan Capital and a downgrade to "strong sell" from Wall Street Zen.

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for REGENXBIO in a note issued to investors on Monday, August 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($2.32) per share for the year, down from their previous estimate of ($1.64). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's Q4 2025 earnings at $0.23 EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($2.98) EPS and FY2029 earnings at ($2.03) EPS.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.13) by ($0.25). The company had revenue of $21.36 million during the quarter, compared to analysts' expectations of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%.

Other equities research analysts have also issued research reports about the company. Chardan Capital reissued a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Friday, August 8th. Barclays dropped their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. HC Wainwright reissued a "buy" rating and set a $34.00 price objective on shares of REGENXBIO in a research note on Tuesday, August 19th. Royal Bank Of Canada dropped their price objective on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Finally, Wall Street Zen lowered REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $28.38.

REGENXBIO Stock Up 1.5%

NASDAQ:RGNX traded up $0.14 during trading hours on Thursday, hitting $9.11. 257,674 shares of the company's stock traded hands, compared to its average volume of 962,597. The firm has a market cap of $459.89 million, a P/E ratio of -2.65 and a beta of 1.11. REGENXBIO has a 52 week low of $5.03 and a 52 week high of $13.48. The business's fifty day simple moving average is $8.52 and its two-hundred day simple moving average is $8.07.

Institutional Investors Weigh In On REGENXBIO

Hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC bought a new stake in REGENXBIO during the first quarter worth about $484,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of REGENXBIO in the 1st quarter valued at about $123,000. Price T Rowe Associates Inc. MD lifted its stake in shares of REGENXBIO by 9.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after acquiring an additional 1,982 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of REGENXBIO by 370.1% in the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock valued at $743,000 after acquiring an additional 75,652 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of REGENXBIO by 34.0% in the 4th quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock valued at $374,000 after acquiring an additional 12,285 shares during the last quarter. Institutional investors own 88.08% of the company's stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.